Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Exclusion Criteria

• •Known history or evidence of brain metastases.
• •Require any antineoplastic therapy.
• •History of prior treatment with anti-LAG3.
• •Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.
• •Had any investigational cytotoxic drug within 4 weeks prior to study treatment.
• •Have received any investigational drugs, a live vaccine, any allergen hyposensitization therapy, growth factors or major surgery within 28 days prior to study treatment.
• •Major surgery
• •Hypersensitivity reaction to any monoclonal antibody.
• •Has an active known or suspected autoimmune disease.
• •Has a diagnosis of immunodeficiency.
• •Prior tissue or organ allograft or allogeneic bone marrow transplantation.
• •Requires daily supplemental oxygen
• •History of interstitial lung disease.
• •Significant heart disease
• •History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.
• •Infection with HIV or hepatitis B or C at screening.
• •Has an active infection.
• •Unable to have blood drawn.
• •Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• •Prior life-threatening toxicity to anti-PD-1, anti-PD-L1, anti-PD-L2,or anti-CTLA4
• •Woman who are pregnant or breastfeeding.